The use of cannabidiols to treat epilepsy

19 Jun 2018, 5:54 p.m.

Headshot of Helen

Statement from Professor Helen Cross, a consultant in paediatric neurology and the Prince of Wales’ Chair of Childhood Epilepsy:At Great Ormond Street Hospital, we have led and participated in two international clinical trials looking at the use of cannabidiol, a drug derived from cannabis for children living with two specific forms of epilepsy, Dravet Syndrome and Lennox Gastaut Syndrome.

The results have been extremely positive. The derivative, which has the psycho-active elements removed, reduced seizures by nearly 40 per cent in children with Dravet syndrome when compared with a dummy drug. Lennox Gastaut syndrome is characterised by particularly disabling seizures ‘drop attacks’ that impact quality of life; these seizures were significantly reduced by the drug.

The trials took place under strictly controlled circumstances, using the specific formulation pharmaceutically prepared Epidiolex (GW Pharma). Currently the trial results have been submitted for assessment by the regulatory bodies, the FDA (USA) and EMA (Europe), to consider whether a licence should be issued. We welcome this process which could pave the way for patient prescription.

Cannabis/hemp oils are available for purchase. While they often state that they contain acceptable and very low doses of the psycho-active element (Tetrahydrocannabinol or THC), they are not produced to a pharmaceutical standard and it has been demonstrated even different batches of the same product have variable content. As there is no evidence relating to dose, safety or interaction with other products, doctors cannot within their code of practice prescribe such products. Products with higher content of THC are not currently legal in the UK.

We would ask any patients or their families wishing to explore using these products to talk to their GP, hospital or contact the national charity Young Epilepsy.

To read more about the research carried out at GOSH please explore the following pages

NIHR GOSH Clinical Research Facility celebrates patients and their families with a festive celebration

On Wednesday 18 December we celebrated the festive period at the National Institute for Health Research (NIHR) GOSH Clinical Research Facility (CRF) on the 8th floor of the Southwood building.

New findings from world’s largest study on children with Long-Covid

A new study led by clinicians and researchers at Great Ormond Street Hospital and University College London Great Ormond Street Institute of Child Health has found that 70% of young people in England with Long-Covid recover within two years.

GOSH celebrates its fifth academic training weekend

In early November 70 early career researchers came together for the fifth NIHR GOSH BRC Academic Training Weekend.

Margaret Monckton appointed Chief Financial Officer of Great Ormond Street Hospital

Margaret Monckton has been appointed as Chief Financial Officer (CFO) for Great Ormond Street Hospital NHS Foundation Trust.